Coronavirus Update: Two Treatments Progress As Moderna/Takeda Investigation Concludes
Takeda and Moderna have identified the source of metallic particles in some lots of mRNA-1273 in Japan, but believe the two deaths identified to be coincidental. Pfizer starts protease inhibitor trial, and Rigel reports fostamatinib data.
You may also be interested in...
From clinical trials to in-person sales calls, the pharmaceutical value chain has been tested by the COVID-19 pandemic, but has held up. Nevertheless, recent friction within this chain may be more than a passing irritation.
A third death has been reported in Japan following dosing with Moderna's mRNA vaccine and while an investigation is underway, it is not seen as product-related. Takeda has also signed a production and supply deal with Japan's government for Novavax's nanoparticle vaccine.
Government and companies conducting urgent investigation into two deaths in recipients of Moderna vaccine, the causes of which remain unclear at this stage.